Cepheid last week reported a 28 percent spike in first-quarter revenues driven primarily by strong sales in its clinical diagnostics business, including record sequential growth in clinical reagent sales.

Despite the sales growth, Cepheid reported a net loss of $5.5 million for the quarter, compared to a profit of $527,000 in the first quarter of 2011 — a result that company officials chalked up to "unanticipated challenges" associated with a manufacturing scale-up.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.